Bain Capital Public Equity Management’s Voyager Therapeutics VYGR Stock Holding History

Bain Capital Public Equity Management’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,176,470	Closed	-$10.5M	–	76
2017 Q2	$10.5M	Sell	1,176,470 -337,612	-22%	-$3.4M	0.63%	35
2017 Q1	$20M	Hold	1,514,082	–	–	1.42%	24
2016 Q4	$19.3M	Hold	1,514,082	–	–	1.31%	28
2016 Q3	$18.2M	Hold	1,514,082	–	–	1.18%	23
2016 Q2	$16.6M	Sell	1,514,082 -8,928	-0.6%	-$109K	0.7%	29
2016 Q1	$13.3M	Sell	1,523,010 -3,460	-0.2%	-$39.2K	0.49%	28
2015 Q4	$33.4M	Buy	+1,526,470	New	+$35.2M	0.96%	30

Other funds holding VYGR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bain Capital Public Equity Management's VYGR Position: Q3 2017 in Review

Bain Capital Public Equity Management sold out of Voyager Therapeutics (VYGR) in Q3 2017, closing a stake of 1,176,470 shares — an estimated $10.5M sold.

Bain Capital Public Equity Management first reported a position in VYGR in Q4 2015 and held it in 7 quarters. The position peaked at $33.4M in Q4 2015. 75 funds tracked by Wall St. Rank hold VYGR as of Q3 2017.

Bain Capital Public Equity Management reported no remaining Voyager Therapeutics position as of Q3 2017 after selling out during the quarter.
Bain Capital Public Equity Management sold 1,176,470 Voyager Therapeutics shares in Q3 2017, an estimated $10.5M.
Bain Capital Public Equity Management first reported a position in Voyager Therapeutics in Q4 2015 and held it in 7 quarters.
Bain Capital Public Equity Management's Voyager Therapeutics position peaked at $33.4M in Q4 2015.
75 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2017.

Based on Bain Capital Public Equity Management's 13F filing for Q3 2017, filed 14 Nov 2017.